title: Preventive Strategies for Patients at Risk of Medication-related Osteonecrosis of the Jaw.
abstract: For patients at risk of osteonecrosis of the jaw (ONJ), information can be provided by the pharmaceutical manufacturer, pharmacist, prescribing physician, dentist, and oral and maxillofacial surgeon. Prevention strategies to reduce the incidence of osteonecrosis should be applied as soon as it is determined that a patient will be placed on antiresorptive medication. Proper screening involves a comprehensive oral examination with radiographs followed by oral hygiene instruction and necessary dental treatment; surgical techniques and adjunctive therapies that favor optimum healing of bone and soft tissue decrease the risk of ONJ. No dental procedures are absolutely contraindicated.
authors: Department of Oral and Maxillofacial Sciences, Faculty of Dentistry, Dalhousie University, 5981 University Avenue, Halifax, Nova Scotia B3H 4R2, Canada. Electronic address: reginald.goodday@dal.ca.
authors: Reginald H
authors: RH
authors: Goodday
mesh_terms: D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000517:prevention & control*; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D003945:Diagnosis, Oral; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D009910:Oral Hygiene; D010353:Patient Education as Topic; D011861:Radiography, Dental; D012307:Risk Factors
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates
keywords: Antiresorptives; Bisphosphonates; Osteonecrosis of the jaw (ONJ); Prevention; Risk